Characteristics | VLDA, n = 26 | DAPSA ≤ 4, n = 52* | cDAPSA ≤ 4, n = 65 |
---|---|---|---|
Male, n (%) | 17 (65.4) | 32 (66.7) | 44 (67.7) |
Age, yrs, mean (SD) | 53.7 (14.4) | 52.0 (13.5) | 52.1 (13.3) |
CRP, mg/l, mean (SD) | 1.9 (1.9) | 1.9 (2.0) | 2.2 (2.6) |
Comorbidities, n (%) | |||
Dyslipidemia | 11 (42.3) | 21 (43.8) | 24 (36.9) |
HBP | 9 (34.6) | 11 (22.9) | 15 (23.1) |
Obesity | 9 (34.6) | 15 (31.3) | 22 (33.8) |
DM | 3 (11.5) | 4 (8.3) | 7 (10.8) |
PsA characteristics | |||
PsA clinical pattern, n (%) | |||
Axial | 0 (0.0) | 1 (2.1) | 2 (3.1) |
Peripheral | 22 (84.6) | 42 (87.5) | 57 (87.7) |
Mixed | 4 (15.4) | 5 (10.4) | 6 (9.2) |
Dactylitis, n (%) | 13 (50.0) | 22 (45.8) | 31 (47.7) |
Enthesitis, n (%) | 13 (50.0) | 17 (35.4) | 26 (40.0) |
Familial history, n (%) | |||
Psoriasis | 14 (53.8) | 26 (54.2) | 36 (55.4) |
PsA | 0 (0.0) | 4 (8.3) | 5 (7.7) |
Ankylosing spondylitis | 1 (3.8) | 1 (2.1) | 1 (1.5) |
PsA duration, yrs, mean (SD) | 9.5 (9.1) | 9.4 (7.5) | 8.9 (6.8) |
Skin symptoms duration, yrs, mean (SD) | 22.0 (16.7) | 19.3 (15.4) | 19.2 (14.7) |
Articular symptoms duration, yrs, mean (SD) | 12.0 (9.8) | 11.5 (8.8) | 11.2 (8.5) |
PsA status at study visit | |||
Radiologic findings | |||
Erosions in hands and/or feet, n (%) | 13 (50.0) | 21 (43.8) | 27 (41.5) |
PsAID, mean (SD) | 1.1 (1.2) | 1.3 (1.5) | 1.7 (1.6) |
PASI, mean (SD) | 0.4 (0.8) | 0.6 (1.1) | 0.7 (1.4) |
HAQ, mean (SD) | 0.06 (0.1) | 0.1 (0.3) | 0.2 (0.3) |
DAPSA, mean (SD) | 1.5 (1.6) | 1.6 (1.1) | 2.2 (1.4) |
cDAPSA, mean (SD) | 1.3 (1.6) | 1.5 (1.0) | 2.0 (1.4) |
↵* There were 52 patients in DAPSA remission, but complete information was available for only 48. VLDA: very low disease activity; CRP: C-reactive protein; HBP: high blood pressure; DM: diabetes mellitus; PASI: Psoriasis Area and Severity Index; HAQ: Health Assessment Questionnaire; PsAID: Psoriatic Arthritis Impact of Disease; DAPSA: Disease Activity Index for Psoriatic Arthritis; cDAPSA: clinical DAPSA; PsA: psoriatic arthritis.